Consistent findings from five SGLT-2 inhibitor trials in people with symptomatic heart failure have demonstrated that SGLT-2 inhibition reduces the risk of cardiovascular death or hospitalisation for heart failure among this population [4, 6, 7, 11–14]. The gene discussed is SLC5A2; the disease is heart failure.